Across TCGA pan-cancer cohorts, SLX1A-SULT1A3 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of SLX1A-SULT1A3’s most consistent transcriptional readouts.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where SLX1A-SULT1A3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SLX1A-SULT1A3 is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.
HNSC, KIRC, and BLCA are the cancer types where SLX1A-SULT1A3 tumor–normal differential expression is most reproducible.
RNA tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLX1A-SULT1A3 RNA (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.